This site is new - feedback and suggestions welcome via GitHub issues.

#steatohepatitis — Saturday, February 21, 2026 (1 items)

0 ℹ Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. (linkinghub.elsevier.com) robot Noureddin M … Loomba R The Lancet 2026-02-21 #clinical trial #therapeutics #fibrosis #steatohepatitis